Teammates: Brandon Wilson, Jahrane Dale, Riancy Li, Olachi Oleru, Ritish Patnaik, Cameron Statton, Stephanie Yang
University: Columbia University
Sector: Healthcare, Medical Diagnostics Devices, Cancer Screening
Luso Labs aims to provide automated, accurate and accessible cervical cancer screening around the world. Rural areas in low and middle-income countries (LMICs) lack the resources needed to provide annual pap smears. Instead, healthcare workers usually perform visual inspection with acetic acid (VIA) screening, in which they apply diluted vinegar to the cervix and inspect the cervix for white precancerous lesions. Though the World Health Organization supports VIA, many public hospitals, NGOs and independent gynecologists in LMICs have seen VIA’s accuracy decrease in rural areas (58%-83%), where it is performed by healthcare workers with limited gynecological training.
447,000 women in LMICs are expected to die from cervical cancer in 2030, partly due to a lack of accurate screening methods. Luso Labs will meet this clinical need for improved cervical cancer screening with the cerVIA system. Through an easy-to-use image acquisition device, cerVIA provides healthcare workers with computer-aided analyses of patient VIA images for cancerous cervical lesions. Healthcare workers will use the analyses to complement their own assessments, resulting in more objective and accurate VIA screening. The cerVIA includes a handheld, speculum-fitted device that captures filtered, high-quality images of the patient cervix. The device connects to any Android smartphone, and through a proprietary machine learning algorithm in our Android application, images are analyzed for precancerous lesions, producing a color map that highlights the lesions. When diagnosing a patient, healthcare workers will examine the map overlayedon the initial image. By improving VIA testing, cerVIA can help save millions of women in LMICs.